Gallwas, Julia

[["dc.bibliographiccitation.firstpage","431"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Cancer"],["dc.bibliographiccitation.volume","18"],["dc.contributor.author","Semmlinger, Anna"],["dc.contributor.author","von Schoenfeldt, Viktoria"],["dc.contributor.author","Wolf, Verena"],["dc.contributor.author","Meuter, Alexandra"],["dc.contributor.author","Kolben, Theresa Maria"],["dc.contributor.author","Kolben, Thomas"],["dc.contributor.author","Zeder-Goess, Christine"],["dc.contributor.author","Weis, Florian"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Wuerstlein, Rachel"],["dc.contributor.author","Hermelink, Kerstin"],["dc.contributor.author","Schmoeckel, Elisa"],["dc.contributor.author","Harbeck, Nadia"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Mahner, Sven"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Ditsch, Nina"],["dc.date.accessioned","2020-06-15T14:32:25Z"],["dc.date.available","2020-06-15T14:32:25Z"],["dc.date.issued","2018"],["dc.description.abstract","In various cancers, overexpression of cyclooxygenase (COX)-2 and elevated prostaglandin (PG) E2 synthesis have been associated with tumor development and progression. The potential of COX-2 inhibitors in cancer prevention and treatment has been shown repeatedly; however, their clinical use is limited due to toxicity. PGE2 signals via EP receptors 1-4, whose functions are analyzed in current research in search for targeted anti-PG therapies. EP2 and EP4 rather promote tumorigenesis, while the role of EP3, especially in breast cancer, is not yet clear and both pro- and anti-tumorigenic effects have been described. Our study evaluates EP3 receptor expression in sporadic breast cancer and its association with clinicopathological parameters, progression-free and overall survival."],["dc.identifier.doi","10.1186/s12885-018-4286-9"],["dc.identifier.pmid","29661238"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66273"],["dc.language.iso","en"],["dc.relation.issn","1471-2407"],["dc.title","EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","50"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Experimental & Clinical Cancer Research"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Heublein, Sabine"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Egger, Markus"],["dc.contributor.author","Karsten, Uwe"],["dc.contributor.author","Goletz, Steffen"],["dc.contributor.author","Angele, Martin"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Ditsch, Nina"],["dc.date.accessioned","2020-06-15T14:32:13Z"],["dc.date.available","2020-06-15T14:32:13Z"],["dc.date.issued","2015-05-19"],["dc.description.abstract","Mucin-1 (MUC1, CD227), more widely known as CA15-3, is an abundantly expressed epithelial cell surface antigen and has evolved to be the most predictive serum tumour marker in breast cancer. PankoMab-GEX™, which is currently being evaluated for its therapeutic efficacy in a phase IIb clinical trial, is a glyco-optimized anti-MUC1 antibody specifically recognizing a tumour-associated MUC1 epitope (TA-MUC1). The current study aimed to analyse the immunoreactivity of PankoMabGEX™ and its correlation with established clinico-pathological variables including 10-year and overall survival in a large cohort of breast cancer patients."],["dc.identifier.doi","10.1186/s13046-015-0152-7"],["dc.identifier.pmid","25986064"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66270"],["dc.language.iso","en"],["dc.relation.eissn","1756-9966"],["dc.relation.issn","1756-9966"],["dc.title","Immunoreactivity of the fully humanized therapeutic antibody PankoMab-GEX™ is an independent prognostic marker for breast cancer patients"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0127072"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","PLoS One"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Heublein, Sabine"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Meindl, Alfons"],["dc.contributor.author","Angele, Martin"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Ditsch, Nina"],["dc.date.accessioned","2020-06-15T14:32:17Z"],["dc.date.available","2020-06-15T14:32:17Z"],["dc.date.issued","2015"],["dc.description.abstract","Since BRCA1 associated breast cancers are frequently classified as hormone receptor negative or even triple negative, the application of endocrine therapies is rather limited in these patients. Like hormone receptors that bind to estrogen or progesterone, thyroid hormone receptors (TRs) are members of the nuclear hormone receptor superfamily. TRs might be interesting biomarkers - especially in the absence of classical hormone receptors. The current study aimed to investigate whether TRs may be specifically expressed in BRCA1 associated cancer cases and whether they are of prognostic significance in these patients as compared to sporadic breast cancer cases. This study analyzed TRα and TRβ immunopositivity in BRCA1 associated (n = 38) and sporadic breast cancer (n = 86). Further, TRs were studied in MCF7 (BRCA1 wildtype) and HCC3153 (BRCA1 mutated) cells. TRβ positivity rate was significantly higher in BRCA1 associated as compared to sporadic breast cancers (p = 0.001). The latter observation remained to be significant when cases that had been matched for clinicopathological criteria were compared (p = 0.037). Regarding BRCA1 associated breast cancer cases TRβ positivity turned out to be a positive prognostic factor for five-year (p = 0.007) and overall survival (p = 0.026) while TRα positivity predicted reduced five-year survival (p = 0.030). Activation of TRβ resulted in down-modulation of CTNNB1 while TRα inhibition reduced cell viability in HCC3153. However, only BRCA1 wildtype MCF7 cells were capable of rapidly degrading TRα1 in response to T3 stimulation. Significantly, this study identified TRβ to be up-regulated in BRCA1 associated breast cancer and revealed TRs to be associated with patients' prognosis. TRs were also found to be expressed in triple negative BRCA1 associated breast cancer. Further studies need to be done in order to evaluate whether TRs may become interesting targets of endocrine therapeutic approaches, especially when tumors are triple-negative."],["dc.identifier.doi","10.1371/journal.pone.0127072"],["dc.identifier.pmid","26029931"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66271"],["dc.language.iso","en"],["dc.relation.issn","1932-6203"],["dc.title","Thyroid Hormone Receptors Predict Prognosis in BRCA1 Associated Breast Cancer in Opposing Ways"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","4529"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","21"],["dc.contributor.affiliation","Eppich, Simon; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, simon.eppich@gmx.de"],["dc.contributor.affiliation","Kuhn, Christina; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, christina.kuhn@med.uni-muenchen.de"],["dc.contributor.affiliation","Schmoeckel, Elisa; \t\t \r\n\t\t Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337 Munich, Germany, elisa.schmoeckel@med.uni-muenchen.de"],["dc.contributor.affiliation","Mayr, Doris; \t\t \r\n\t\t Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337 Munich, Germany, doris.mayr@med.uni-muenchen.de"],["dc.contributor.affiliation","Mahner, Sven; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, sven.mahner@med.uni-muenchen.de"],["dc.contributor.affiliation","Jeschke, Udo; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, udo.jeschke@med.uni-muenchen.de\t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany, udo.jeschke@med.uni-muenchen.de"],["dc.contributor.affiliation","Gallwas, Julia; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, julia.gallwas@med.uni-muenchen.de\t\t \r\n\t\t Department of Gynecology and Obstetrics, Georg August University Goettingen, University Medicine, 37075 Goettingen, Germany, julia.gallwas@med.uni-muenchen.de"],["dc.contributor.affiliation","Heidegger, Helene Hildegard; \t\t \r\n\t\t Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany, Helene.heidegger@med.uni-muenchen.de"],["dc.contributor.author","Eppich, Simon"],["dc.contributor.author","Kuhn, Christina"],["dc.contributor.author","Schmoeckel, Elisa"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Mahner, Sven"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Heidegger, Helene Hildegard"],["dc.date.accessioned","2021-04-14T08:25:04Z"],["dc.date.available","2021-04-14T08:25:04Z"],["dc.date.issued","2020"],["dc.date.updated","2022-09-06T10:50:59Z"],["dc.identifier.doi","10.3390/ijms21124529"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81515"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","MSX1—A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2117"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","2123"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Eggersmann, Tanja K"],["dc.contributor.author","Baumeister, Philipp"],["dc.contributor.author","Kumbrink, Jorg"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Schmoeckel, Elisa"],["dc.contributor.author","Thaler, Christian J"],["dc.contributor.author","Dannecker, Christian"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Nagler, Thomas"],["dc.contributor.author","Mahner, Sven"],["dc.contributor.author","Sharaf, Kariem"],["dc.contributor.author","Gallwas, Julia K. S."],["dc.date.accessioned","2020-06-15T14:32:37Z"],["dc.date.available","2020-06-15T14:32:37Z"],["dc.date.issued","2020-04"],["dc.description.abstract","The incidence of human papilloma virus (HPV)-related head and neck squamous cell carcinoma (HNSCC) has been increasing in the last decades. Analysis of oral brushing or rinsing samples for screening or stratification could potentially improve screening and prevention."],["dc.identifier.doi","10.21873/anticanres.14170"],["dc.identifier.pmid","32234904"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66276"],["dc.language.iso","en"],["dc.relation.eissn","1791-7530"],["dc.relation.issn","0250-7005"],["dc.title","Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","121"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Histochemistry & Cytochemistry"],["dc.bibliographiccitation.lastpage","129"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Ditsch, Nina"],["dc.contributor.author","Toth, Bettina"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Lenhard, Miriam"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Weissenbacher, Tobias"],["dc.contributor.author","Dannecker, Christian"],["dc.contributor.author","Friese, Klaus"],["dc.contributor.author","Jeschke, Udo"],["dc.date.accessioned","2020-06-15T13:54:32Z"],["dc.date.available","2020-06-15T13:54:32Z"],["dc.date.issued","2012-02"],["dc.description.abstract","In this study, we analyzed vitamin D receptor (VDR) expression and survival in a breast cancer patient cohort of 82 breast cancer patients. Immunohistochemical analysis was possible in 91.5% of the patients (75/82). Staining was evaluated using the semi-quantitative assay according to Remmele and Stegner (immunoreactivity score [IRS]). IRS 0-1 was negative/very low, IRS 2-4 was moderate to high, and IRS 6-12 was high. Statistical analysis was performed by Spearman's correlation test (p<0.05 significant). Overall survival was analyzed using Kaplan-Meier estimations. Only 6 patients had a negative IRS. Moderate IRS values were present in 20 patients. Most of the patients had a high IRS (49). For survival analysis, data were dichotomized (IRS 0-4: negative to moderate and IRS 6-12: high VDR expression). In univariate analysis, VDR expression showed significant differences in progression-free survival (PFS) and overall survival (OS). Patients with high IRS scores showed significantly better PFS and OS than patients with moderate/negative IRS scores for VDR expression. Tumor size was significantly correlated to PFS. When analyzed separately, the three different IRS groups showed significant differences in VDR expression. The present data suggest that VDR expression in breast cancer tissue may be of clinical significance, and the results provide evidence that VDR may be a factor with prognostic relevance."],["dc.identifier.doi","10.1369/0022155411429155"],["dc.identifier.pmid","22108646"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66265"],["dc.language.iso","en"],["dc.relation.eissn","1551-5044"],["dc.relation.issn","0022-1554"],["dc.title","The association between vitamin D receptor expression and prolonged overall survival in breast cancer"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3185"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Anticancer Research"],["dc.bibliographiccitation.lastpage","3190"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Kolben, Thomas"],["dc.contributor.author","Hary, Thomas"],["dc.contributor.author","Holdt, Lesca M"],["dc.contributor.author","Schwarz, Theresa M"],["dc.contributor.author","Goess, Christine"],["dc.contributor.author","Wuerstlein, Rachel"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Toth, Bettina"],["dc.contributor.author","Weissenbacher, Tobias"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Harbeck, Nadia"],["dc.contributor.author","Ditsch, Nina"],["dc.date.accessioned","2020-06-15T14:32:45Z"],["dc.date.available","2020-06-15T14:32:45Z"],["dc.date.issued","2016-06"],["dc.description.abstract","The thyroid hormones free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH) and vitamin D seem to be involved in the process of differentiation and proliferation of breast tissue. Little is known about these factors in breast cancer 1 and 2 (BRCA1/BRCA2)-mutation carriers with breast cancer (BC). The purpose of this investigation was to evaluate the association of thyroid gland function and vitamin D with BC in patients with BRCA mutations."],["dc.identifier.pmid","27272846"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66278"],["dc.language.iso","en"],["dc.relation.eissn","1791-7530"],["dc.title","Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1154"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Dietlmeier, Sebastian"],["dc.contributor.author","Ye, Yao"],["dc.contributor.author","Kuhn, Christina"],["dc.contributor.author","Vattai, Aurelia"],["dc.contributor.author","Vilsmaier, Theresa"],["dc.contributor.author","Schröder, Lennard"],["dc.contributor.author","Kost, Bernd P."],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Mahner, Sven"],["dc.contributor.author","Heidegger, Helene Hildegard"],["dc.date.accessioned","2020-06-03T10:02:30Z"],["dc.date.available","2020-06-03T10:02:30Z"],["dc.date.issued","2020-01-24"],["dc.description.abstract","Recently our study identified EP3 receptor and galectin-3 as prognosticators of cervical cancer. The aim of the present study was the analysis of EP2 as a novel marker and its association to EP3, galectin-3, clinical pathological parameters and the overall survival rate of cervical cancer patients. Cervical cancer tissues (n = 250), as also used in our previous study, were stained with anti-EP2 antibodies employing a standardized immunohistochemistry protocol. Staining results were analyzed by the IRS scores and evaluated for its association with clinical-pathological parameters. H-test of EP2 percent-score showed significantly different expression in FIGO I-IV stages and tumor stages. Kaplan-Meier survival analyses indicated that EP3-negative/EP2-high staining patients (EP2 IRS score ≥2) had a significantly higher survival rate than the EP3-negative/EP2-low staining cases (p = 0.049). In the subgroup of high galectin-3 expressing patients, the group with high EP2 levels (IRS ≥2) had significantly better survival rates compared to EP2-low expressing group (IRS <2, p = 0.044). We demonstrated that the EP2 receptor is a prognostic factor for the overall survival in the subgroup of negative EP3 and high galectin-3 expressed cervical cancer patients. EP2 in combination with EP3 or galectin-3 might act as prognostic indicators of cervical cancer. EP2, EP3, and galectin-3 could be targeted for clinical diagnosis or endocrine treatment in cervical cancer patients, which demands future investigations."],["dc.identifier.doi","10.1038/s41598-020-58095-3"],["dc.identifier.pmid","31980713"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66140"],["dc.language.iso","en"],["dc.relation.issn","2045-2322"],["dc.title","The prostaglandin receptor EP2 determines prognosis in EP3-negative and galectin-3-high cervical cancer cases"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","569"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Cancer Research and Clinical Oncology"],["dc.bibliographiccitation.lastpage","577"],["dc.bibliographiccitation.volume","146"],["dc.contributor.author","Czogalla, Bastian"],["dc.contributor.author","Pham, Deborah"],["dc.contributor.author","Trillsch, Fabian"],["dc.contributor.author","Rottmann, Miriam"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Burges, Alexander"],["dc.contributor.author","Mahner, Sven"],["dc.contributor.author","Kirchner, Thomas"],["dc.contributor.author","Jeschke, Udo"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Schmoeckel, Elisa"],["dc.date.accessioned","2020-06-15T14:32:29Z"],["dc.date.available","2020-06-15T14:32:29Z"],["dc.date.issued","2020-03"],["dc.description.abstract","Programmed death-ligand 1 (PD-L1) has become a widely used predictive biomarker for therapy with checkpoint inhibitors in a variety of cancers. Here, we studied the expression of PD-L1 in squamous cell carcinomas of the vulva (SCCV) with regard to HPV status via its surrogate marker p16. Additionally, the status of PD-L1 and p16 were analyzed for prognostic information and potential correlation to tumor-infiltrating lymphocytes (TILs)."],["dc.identifier.doi","10.1007/s00432-020-03126-9"],["dc.identifier.pmid","32025868"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66274"],["dc.language.iso","en"],["dc.relation.eissn","1432-1335"],["dc.relation.issn","0171-5216"],["dc.title","PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","665"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Oncology Letters"],["dc.bibliographiccitation.lastpage","671"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Ditsch, Nina"],["dc.contributor.author","Mayr, Doris"],["dc.contributor.author","Lenhard, Miriam"],["dc.contributor.author","Strauss, Carolin"],["dc.contributor.author","Vodermaier, Andrea"],["dc.contributor.author","Gallwas, Julia"],["dc.contributor.author","Stoeckl, Doris"],["dc.contributor.author","Graeser, Monika"],["dc.contributor.author","Weissenbacher, Tobias"],["dc.contributor.author","Friese, Klaus"],["dc.contributor.author","Jeschke, Udo"],["dc.date.accessioned","2020-06-15T14:34:06Z"],["dc.date.available","2020-06-15T14:34:06Z"],["dc.date.issued","2012-10"],["dc.description.abstract","Non-steroidal nuclear receptors play a major role in breast cancer development. A correlation among, and possible prognostic function of, the members of the nuclear receptor superfamily has been discussed controversially over the years. Hence, we conducted a quantification of the different expression levels of the thyroid receptor (TR), retinoid X receptor (RXR), peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) in malignant breast tumour tissue samples. Patients diagnosed and treated for breast cancer between 1990 and 2000 were included. Receptor expression was detected by immunohistochemical staining. Correlation analyses for the expression of the receptors were performed for the clinical and histopathological data. The paraffin-embedded tissue from 82 breast cancer patients was available. The different steroid receptors showed varying results when correlated with known histopathological markers. TRα2 demonstrated the most significant correlations with steroid hormone receptors. Significant correlations between the major isoforms of TR, and between RXR, PPAR and VDR, were demonstrated in the patient sample. The immunohistochemical association of these receptors may provide the first proof of an interaction on the molecular level. This assumption awaits confirmation in studies with larger cohorts."],["dc.identifier.doi","10.3892/ol.2012.799"],["dc.identifier.pmid","23205080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/66297"],["dc.language.iso","en"],["dc.relation.issn","1792-1074"],["dc.title","Correlation of thyroid hormone, retinoid X, peroxisome proliferator-activated, vitamin D and oestrogen/progesterone receptors in breast carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dspace.entity.type","Publication"]]